Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

While the oral contraceptive (OC) Yasmin has been the focus of interest in the United States for its potential in treating premenstrual syndrome, its safety has been questioned by Dutch medical officials, who are calling for more epidemiological data on the potential risk for venous thrombosis.

Yasmin is the focus of Dutch safety alert